Joseph Gligorov1, Giuseppe Curigliano2, Volkmar Müller3, Ann Knoop4, Valerie Jenkins5, Sunil Verma6, Stuart Osborne7, Sabine Lauer7, Zuzana Machackova7, Lesley Fallowfield5, Xavier Pivot8. 1. APHP Tenon, IUC-UPMC, Sorbonne University, Paris, France. Electronic address: joseph.gligorov@aphp.fr. 2. European Institute of Oncology, Milan, Italy. 3. University Medical Center, Hamburg, Germany. 4. Copenhagen University Hospital, Copenhagen, Denmark. 5. Sussex Health Outcomes, Research & Education in Cancer (SHORE-C), University of Sussex, East Sussex, UK. 6. Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. 7. F. Hoffmann-La Roche Ltd, Basel, Switzerland. 8. University Hospital Jean Minjoz, Besançon, France.
Abstract
AIM: To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166). PATIENTS AND METHODS: Patients with HER2-positive early breast cancer completed (neo)adjuvantchemotherapy and were randomised to receive four cycles of SC trastuzumab, via single-use injection device (SID; Cohort 1) or hand-held syringe (Cohort 2), followed by four cycles of IV, or vice versa (the crossover period presented here) as part of their 18 standard cycles of adjuvant trastuzumab treatment. Adverse events (AEs) were reported using standard criteria. RESULTS: Overall, fewer AEs were reported during the IV treatment periods, regardless of administration sequence (IV→SC or SC→IV). Differences in AEs between the SC and IV periods were partly due to variances in grade 1 and 2 local injection site reactions (ISRs) and systemic administration-related reactions (ARRs) and these occurred mainly during SC treatment, as expected. When ISRs and ARRs were excluded, rates of AEs were higher during the first treatment period, compared with the second, in both treatment sequences; otherwise there was no clear pattern in the type of AEs reported. Rates of clinically important events, including grade ≥3 AEs, serious AEs, AEs leading to study drug discontinuation and cardiac AEs, were low and similar between treatment arms (<5%). There were no grade 4 or 5 AEs. No new safety signals for trastuzumab were observed. CONCLUSIONS: PrefHer revealed that switching from IV to SC trastuzumab (hand-held syringe or SID) or vice versa did not impact the known safety profile of trastuzumab.
RCT Entities:
AIM: To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166). PATIENTS AND METHODS: Patients with HER2-positive early breast cancer completed (neo)adjuvant chemotherapy and were randomised to receive four cycles of SC trastuzumab, via single-use injection device (SID; Cohort 1) or hand-held syringe (Cohort 2), followed by four cycles of IV, or vice versa (the crossover period presented here) as part of their 18 standard cycles of adjuvant trastuzumab treatment. Adverse events (AEs) were reported using standard criteria. RESULTS: Overall, fewer AEs were reported during the IV treatment periods, regardless of administration sequence (IV→SC or SC→IV). Differences in AEs between the SC and IV periods were partly due to variances in grade 1 and 2 local injection site reactions (ISRs) and systemic administration-related reactions (ARRs) and these occurred mainly during SC treatment, as expected. When ISRs and ARRs were excluded, rates of AEs were higher during the first treatment period, compared with the second, in both treatment sequences; otherwise there was no clear pattern in the type of AEs reported. Rates of clinically important events, including grade ≥3 AEs, serious AEs, AEs leading to study drug discontinuation and cardiac AEs, were low and similar between treatment arms (<5%). There were no grade 4 or 5 AEs. No new safety signals for trastuzumab were observed. CONCLUSIONS: PrefHer revealed that switching from IV to SC trastuzumab (hand-held syringe or SID) or vice versa did not impact the known safety profile of trastuzumab.
Authors: S Dent; C Ammendolea; A Christofides; S Edwards; D Incekol; B Pourmirza; S Kfoury; B Poirier Journal: Curr Oncol Date: 2019-02-01 Impact factor: 3.677
Authors: Yohei Ozawa; Kristin C Hicks; Christine M Minnar; Karin M Knudson; Jeffrey Schlom; Sofia R Gameiro Journal: Oncoimmunology Date: 2021-05-03 Impact factor: 8.110
Authors: María Reyes Abad-Sazatornil; Ainhoa Arenaza; Juan Bayo; Jesus García Mata; José María Guinea De Castro; Josefa León; Javier Letellez; Virginia Reguero; Carmen Martínez Chamorro; Antonio Salar Journal: BMC Health Serv Res Date: 2021-04-08 Impact factor: 2.655